Wednesday, GSK plc (NYSE:GSK) revealed data from the ZOSTER-049 long-term follow-up phase 3 trial, which followed participants for up to approximately 11 years following initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV).  The final trial data demonstrate that RZV has maintained efficacy against shingles in adults over 50 for over a decade.  ZOSTER-049 included over 7,000 participants. The results from ZOSTER-049, an extension from two phase 3 clinical trials in adults aged 50 and over (ZOE-50 and ZOE-70), include: 79.7% vaccine efficacy (VE) in adults aged ≥50 cumulatively from year six to year 11 after vaccination.  82.0% VE in adults ≥50 at year 11, showing VE remains high each year after vaccination.  73.1% VE in adults aged ...